Joshua B Wallach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua B Wallach has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Claire Naylor
Drug Discovery Unit, Faculty of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK
1 shared publication- Clifton Earl Barry
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
1 shared publication - Dirk Schnappinger
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, USA
1 shared publication - Gareth Prosser
Microbial Interface Biology, Research Center Borstel, Leibniz Lung Center, 23845 Borstel, Germany
1 shared publication - Heather Kim
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, USA
1 shared publication - Helena Ingrid M. Boshoff
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, 9000 Rockville Pike, Bethesda, Maryland, MD 20892, USA
1 shared publication
Latest Publications
- Open Access
Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis
Globally, Mycobacterium tuberculosis remains a significant disease burden. Although effective treatment regimens exist, drug resistance continues to emerge. This clinical resistance, combined with side effects and protracted treatment times from the current front-line therapies, means there is a need to identify novel agents to combat this disease. Here we report on a new chemical series, identified by whole-cell phenotypic growth inhibition screening that demonstrates significant activity across multiple media. Mode of action studies indicate that this series targets the same biological pathway as Ethambutol (EMB), a drug used in the current frontline treatment of tuberculosis. Screening selected analogues against clinical isolates, resistant to EMB, demonstrated differential sensitivity both across the molecules and against the different specific resistant mutations. The data obtained suggests that this series has potential to be developed into a viable, alternative to EMB. TOC figure:
Open AccessIdentification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis
Globally, Mycobacterium tuberculosis remains a significant disease burden. Although effective treatment regimens exist, drug resistance continues to emerge. This clinical resistance, combined with side effects and protracted treatment times from the current front-line therapies, means there is a need to identify novel agents to combat this disease. Here we report on a new chemical series, identified by whole-cell phenotypic growth inhibition screening that demonstrates significant activity across multiple media. Mode of action studies indicate that this series targets the same biological pathway as Ethambutol (EMB), a drug used in the current frontline treatment of tuberculosis. Screening selected analogues against clinical isolates, resistant to EMB, demonstrated differential sensitivity both across the molecules and against the different specific resistant mutations. The data obtained suggests that this series has potential to be developed into a viable, alternative to EMB. TOC figure: